Profound Medical (PRN) Receives a Buy from Canaccord Genuity

In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Profound Medical (TSXV: PRN). Canaccord Genuity’s analyst Jason Mills reiterates their Buy rating on More »

Maxim Group Maintains a Buy Rating on Actinium Pharmaceuticals (ATNM)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $3. The company’s shares opened today at $0.62. More »